Exploring the mechanisms of Venetoclax resistence via drug
screening and genome-wide CRISPR screening.

a 2023

Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA et al.

Základní údaje

Originální název

Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.

Autoři

LADUNGOVÁ, Adriana ; Helena PESCHELOVÁ ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA; Jiří MAYER a Michal ŠMÍDA

Vydání

The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood, 2023

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Označené pro přenos do RIV

Organizační jednotka

Středoevropský technologický institut

Klíčová slova anglicky

BCL-2 inhibitor; acute myeloid leukemia; MCL1 upregulation

Štítky

NÚVR_CEITEC, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 1. 2026 11:22, Mgr. Petra Trembecká, Ph.D.

Anotace

V originále

Combining Venetoclax, a selective BCL-2 inhibitor, with hypomethylating agents has revolutionized frontline acute myeloid leukemia (AML) treatment. Despite its success, the occurrence of resistance remains a significant concern, limiting the range of available treatment alternatives. Little is known about the mechanism by which the cells escape the treatment. Recent studies have observed MCL1 upregulation in AML cells to promote resistance, and the rationale to use an MCL1 inhibitor became attractive. Although MCL1 inhibitors work exceptionally well in vitro their clinical trials were unsuccessful due to their toxicity. Here, we aim to identify other genes responsible for acquiring resistance and tackle the problem through screening for clinically approved drugs to rapidly benefit the patients with our study.

Návaznosti

MUNI/A/1330/2021, interní kód MU

Název: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IX (Akronym: VýDiTeHeMa IX)

Investor: Masarykova univerzita, Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IX

MUNI/A/1419/2021, interní kód MU

Název: Specifický výzkum v oblasti „Life Sciences“

Investor: Masarykova univerzita, Specifický výzkum v oblasti „Life Sciences“

Přiložené soubory

65th_ASH_Annual_Meeting2023.pdf

Citovat

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA; Jiří MAYER a Michal ŠMÍDA. Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. In The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood. 2023.

@proceedings{2355940,
   author = {Ladungová, Adriana and Peschelová, Helena and Dostálová, Lenka and Lodhi, Yusuf and Gottumukkala, Narendra Varma and Mayer, Jiří and Šmída, Michal},
   booktitle = {The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood},
   keywords = {BCL-2 inhibitor; acute myeloid leukemia; MCL1 upregulation},
   language = {eng},
   title = {Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.},
   url = {https://ashpublications.org/blood/article/142/Supplement%201/5759/505860/Exploring-the-Mechanisms-of-Venetoclax-Resistance},
   year = {2023}
}

TY  - CONF
ID  - 2355940
AU  - Ladungová, Adriana - Peschelová, Helena - Dostálová, Lenka - Lodhi, Yusuf - Gottumukkala, Narendra Varma - Mayer, Jiří - Šmída, Michal
PY  - 2023
TI  - Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.
KW  - BCL-2 inhibitor
KW  - acute myeloid leukemia
KW  - MCL1 upregulation
UR  - https://ashpublications.org/blood/article/142/Supplement%201/5759/505860/Exploring-the-Mechanisms-of-Venetoclax-Resistance
N2  - Combining Venetoclax, a selective BCL-2 inhibitor, with hypomethylating agents has revolutionized frontline acute myeloid leukemia (AML) treatment. Despite its success, the occurrence of resistance remains a significant concern, limiting the range of available treatment alternatives. Little is known about the mechanism by which the cells escape the treatment. Recent studies have observed MCL1 upregulation in AML cells to promote resistance, and the rationale to use an MCL1 inhibitor became attractive. Although MCL1 inhibitors work exceptionally well in vitro their clinical trials were unsuccessful due to their toxicity. Here, we aim to identify other genes responsible for acquiring resistance and tackle the problem through screening for clinically approved drugs to rapidly benefit the patients with our study.
ER  -

LADUNGOVÁ, Adriana; Helena PESCHELOVÁ; Lenka DOSTÁLOVÁ; Yusuf LODHI; Narendra Varma GOTTUMUKKALA; Jiří MAYER a Michal ŠMÍDA. Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening. In \textit{The 65th ASH Annual Meeting and Exposition, San Diego, California, USA in Blood}. 2023.

Přehled o publikaci